Afirma基因表达分类器在重复不确定甲状腺结节中的评估
Afirma将50%结节判为可疑,手术切除后这些结节恶性率为35%,阳性预测值仅35%,低于机构历史Bethesda III(11%)和IV(23%)的恶性率。
要点
- Afirma在重复不确定甲状腺结节中阳性预测值低(35%)。
- 可疑结节手术切除后65%为良性,恶性仅35%。
- Afirma良性结节手术切除后均为良性。
核心结论
- Afirma在不确定甲状腺结节中阳性预测值低,与既往报道一致。
主要发现
- 良性结节中3个(6%)手术切除,最终病理均为良性。
关键数值与推荐
- Afirma可疑结节手术切除恶性率35%,机构历史Bethesda III结节恶性率11%、Bethesda IV结节恶性率23%。
临床怎么用
- Afirma可疑结果需谨慎解读,因其阳性预测值低,可能需结合其他临床信息决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: - Molecular testing in indeterminate thyroid nodules is a rapidly evolving field with variable reported outcomes. OBJECTIVE: - To report our experience at a tertiary thyroid referral center with the Afirma Gene Expression Classifier (Veracyte, San Francisco, California) in repeat fine-needle aspirations of thyroid nodules with a previous indeterminate cytologic result. DESIGN: - Results of cytopathology and the Afirma test were collected from August 2013 to March 2015, as were diagnoses from surgical resection when performed. RESULTS: - One hundred and fifteen thyroid nodules were evaluated by Afirma. The fine-needle aspiration diagnostic categories for these nodules were 100 (87%) Bethesda III, 10 (9%) Bethesda IV, 3 (2%) Bethesda II, 1 (1%) Bethesda V, and 1 (1%) Bethesda I. Afirma results for 52 of the nodules (45%) were benign, 57 (50%) were suspicious, and 6 (5%) specimens yielded no result because of low messenger RNA content. Three of the benign nodules (6%) were treated surgically, and all were benign on final surgical pathology. Forty-six (81%) of the suspicious nodules were treated surgically; final surgical pathology revealed 30 (65%) were benign and 16 (35%) malignant, yielding a positive predictive value of 35%. CONCLUSIONS: - In our experience, 50% of the indeterminate nodules were classified as suspicious by Afirma, with a 35% rate of malignancy in these nodules at surgical resection, in comparison with a historical rate of malignancy at our institution of 11% for Bethesda III nodules and 23% for Bethesda IV. Our use of Afirma is consistent with prior reports in that it has a low positive predictive value in indeterminate thyroid nodules.
引用
- Harrison G, Sosa JA, Jiang X, et al. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules. Arch Pathol Lab Med. 2017. PMID: 28467214. doi:10.5858/arpa.2016-0328-OA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。